Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic…#reopen #xhance #yardley #optn #fda #pdufa #ramymahmoud #mph #eds #item1ariskfactors
Source: Reuters: Health - Category: Consumer Health News Source Type: news